Citi analyst Joanne Wuensch reiterated a purchase score for Johnson & Johnson inventory (NYSE: JNJ) with a worth goal of $285. In accordance with TipRanks, Wuensch has a 3-star score with successful price of fifty.83% in worth predictions. The analyst covers the healthcare sector extensively and lately offered forecasts for main medical giants Boston Scientific, Edwards Lifesciences, and Medtronic. His estimates on JNJ deliver recent enthusiasm into the sector, which has largely stagnated in worth in 2026.
If the Citi analysts’ worth prediction on Johnson & Johnson inventory seems to be correct, an funding of $1,000 may flip into $1,270. That’s an uptick and return on funding (ROI) of roughly 27% from its present worth of $225. It could even be thought of stellar returns, as not each asset available in the market delivers double-digit positive aspects. In accordance with his forecast, JNJ is among the many handpicked video games which are able to making traders’ portfolios swell with earnings.
Why Does Citi Predict Johnson & Johnson Inventory Will Attain $285?
Citi analyst’s bullish worth prediction comes after the pharma big acquired approval from the US Meals and Drug Administration (FDA) for the Caplyta drug. The FDA authorised the drug after evaluating its security and efficacy for the prevention of relapse in schizophrenia. The approval comes after a long-term knowledge analysis by the division and has given it a nod for manufacturing. Round 2.8 million adults within the US endure from schizophrenia, and almost 40% of the sufferers don’t obtain ample care. The approval made Citi analyst give Johnson & Johnson inventory a $285 worth goal.
As well as, the medical firm has two extra medicine within the pipeline that would obtain an FDA nod. If that occurs, Johnson & Johnson inventory may rise additional in worth properly into 2027. Subsequently, an funding in JNJ now may very well be useful for the long run because the fairness is buying and selling at a reduction. Even CNBC’s Mad Cash host, Jim Cramer, has given JNJ a purchase name in a current phase, saying that this low worth is not going to be on the market endlessly, and urged merchants to purchase the dips and accumulate the medical big.
